Abstract
Type 2 diabetes mellitus patients (T2DM) with chronic heart failure (CHF) are at higher risk of hospitalization for HF, nonfatal myocardial infarction (MI) and renal replacement therapy (RRT). The results of the EMPA-REG OUTCOME study presented convincing evidence that the use of empagliflozin in these patients can significantly reduce the frequency of such hospitalizations. The aim of this study was to compare the clinical and economic impact of empagliflozin in combination with standard of care (SoC) vs SoC in reducing the frequency of hospitalizations in T2DM patients with CHF.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
